Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded at Wall Street Zen
by Renee Jackson · The Cerbat GemWall Street Zen upgraded shares of Sensei Biotherapeutics (NASDAQ:SNSE – Free Report) to a hold rating in a research note published on Saturday morning.
Other research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, December 22nd. HC Wainwright downgraded Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $55.00.
Read Our Latest Stock Analysis on Sensei Biotherapeutics
Sensei Biotherapeutics Stock Performance
Sensei Biotherapeutics stock opened at $8.99 on Friday. The stock has a market capitalization of $11.33 million, a P/E ratio of -0.47 and a beta of 0.32. The company’s fifty day moving average price is $9.09 and its 200 day moving average price is $8.86. Sensei Biotherapeutics has a 1 year low of $5.00 and a 1 year high of $18.35.
Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($3.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.11) by $0.49. Sell-side analysts predict that Sensei Biotherapeutics will post -1.17 EPS for the current year.
Insider Buying and Selling at Sensei Biotherapeutics
In other news, major shareholder James Peyer sold 16,295 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.50, for a total value of $187,392.50. Following the completion of the sale, the insider directly owned 161,359 shares in the company, valued at $1,855,628.50. This represents a 9.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 27,907 shares of company stock worth $287,280. Insiders own 23.20% of the company’s stock.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.